Skip to content
mapperlab
← Dashboard
Stock

STAA

STAAR Surgical Co
Health CareHealth Care EquipmentLatest close $326 of 27 marquee funds currently hold1 CUSIP mapped
Current holders
6
27 funds tracked
Ever held
9
Current + past
New this quarter
1
Exited this quarter
1

Marquee-fund ownership over time

Nov 16, 2020Aug 14, 2024May 15, 2025May 15, 2026
Now
6

This quarter's activity

New positions opened

Positions exited

Current holders

Sorted by tenure (longest first)
FundEntry priceLatest closeReturn on entry
Renaissance Technologies re-entered$38$32-16%
Citadel Advisors$35$32-8%
Two Sigma Investments re-entered$35$32-8%
D.E. Shaw re-entered$35$32-8%
Millennium Management$35$32-8%
Point72 Asset Management$32$32+1%

“Return on entry” is the price-only move from the fund's first disclosure to today — it ignores any adds, trims, or dividends. A fund that built its position over multiple quarters has a true cost basis somewhere between entry price and latest close; this figure is the upper bound.

Past holders

Funds that exited at some point
FundEntry → ExitReturn
AQR Capital Management 2× in & out→ $32+22%
Bridgewater Associates→ $16-89%
Maverick Capital→ $114+44%

Insider activity

Form 4 — officers, directors, 10%+ owners

Filed within two business days of each transaction by anyone with material insider status at STAAR SURGICAL CO. Pair with the holders table above as a sanity check: heavy insider buying alongside marquee-fund accumulation is the strongest accumulation signal; heavy insider selling alongside fund exits is the strongest distribution signal.

Filings · last 30d
5
Filings · last 90d
12
Total on file
417
Recent SEC buffer
Most recent
May 19, 2026

30d / 90d windows measured from May 19, 2026 — the most recent Form 4 on file — not from today.

Showing 15 of 417 recent Form 4 filings. Browse all on EDGAR ↗

Fundamentals

XBRL · STAAR Surgical Co

Annual figures sourced directly from STAAR Surgical Co's 10-K / 10-Q filings via SEC EDGAR XBRL. Latest fiscal year and the year-over-year change, with up to ten years of history.

Revenue
$239.44M
FY2026-24% YoY
Net income
-$80.45M
FY2026-298% YoY
EPS (diluted)
$-1.62
FY2026-295% YoY
Free cash flow(?)
-$40.05M
FY2026-422% YoY

Recent SEC filings

10-K · 10-Q · 8-K · 13D/G · proxy

The most recent material filings for STAAR SURGICAL CO — earnings, material events, ownership disclosures, proxy statements. Form 4 insider activity is shown in the panel above.

Trade history

Every open→close lifecycle across tracked funds
FundOpen dateClose dateOpen priceClose price / currentReturn
Point72 Asset ManagementQ2 2026open$32$32+1%
Renaissance TechnologiesQ1 2026open$16$32+96%
AQR Capital ManagementQ4 2025Q2 2026$26$32+22%
Two Sigma InvestmentsQ2 2025open$18$32+77%
D.E. ShawQ1 2025open$15$32+110%
AQR Capital ManagementQ4 2024Q2 2025$27$18-33%
Citadel AdvisorsQ3 2024open$35$32-8%
Two Sigma InvestmentsQ3 2024Q1 2025$35$15-56%
D.E. ShawQ3 2024Q4 2024$35$27-22%
Millennium ManagementQ3 2024open$35$32-8%
Renaissance TechnologiesQ3 2024Q4 2025$38$26-32%
Bridgewater AssociatesQ3 2021Q1 2025$139$16-89%
Maverick CapitalQ4 2020Q2 2021$79$114+44%
Caveats
  • Covers only the 27 marquee funds tracked here, not the full institutional universe. A “0 holders” reading does not mean unowned.
  • Heavy funds (Renaissance Technologies, Citadel Advisors, Soros Fund Management, Two Sigma Investments, D.E. Shaw, AQR Capital Management, Millennium Management, Point72 Asset Management) use 8-quarter snapshots, so their pre-2024 history is missing.
  • “Current” reflects each fund's most recent 13F — filings lag the actual trade by up to 45 days; positions shown may have changed since.
  • Cost = price at the entry filing date. Re-entered positions show the most recent open lot.
  • Options, ADRs, and unmapped CUSIPs are excluded from the follower-backtest pipeline that produces these snapshots, so certain holding types won't appear here.